I’m Diane Brady. From transformative weight loss treatment to a potential blockbuster for Alzheimer's, Dave Ricks of Eli ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...

In the company's second-quarter results call, Lilly's chief scientific officer Daniel Skovronsky revealed that orally active anti-tau drug LY3372689 – an O-GlcNAcase (OGA) inhibitor – failed a ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

The company describes the precision medicine test as the first ... JPM24: Caris crafts collabs with AbbVie, Flatiron to bring ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

The drug developed by U.S. pharmaceutical giant Eli Lilly and Co. will be offered to patients experiencing dementia and mild ...